Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: An open label, randomised, crossover trial

Gut

Volumn 63, Issue 9, 2014, Pages 1410-1415

  Liu, Kevin S H ^a   Hung, Ivan F N ^a   Seto, W K Walter ^a   Tong, Teresa ^a   Hsu, Axel S J ^a   Lam, Frank Y F ^a   But, David Y K ^a   Wong, S Y ^a   Leung, Wai K ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL CLEARANCE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEFECATION HABIT; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HELICOBACTER INFECTION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING;

13C-UREA BREATH TEST; ANTIBIOTICS; HELICOBACTER PYLORI - TREATMENT;

ADULT; AGED; AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BREATH TESTS; CHINA; CLARITHROMYCIN; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; TETRACYCLINE; TREATMENT OUTCOME;

EID: 84905440362     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306120     Document Type: Article

References (30)

1. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273.
2. International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-240.
3. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradicaiton to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94. (Pubitemid 38082812)
4. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996;1:138-44. (Pubitemid 126671139)
5. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25. (Pubitemid 47206706)
6. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
7. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
8. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
9. Chung JW, Jung YK, Kim YJ, et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-80.
10. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004;10:668-71. (Pubitemid 38351533)
11. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43. (Pubitemid 36774140)
12. Tepes B, O'Connor A, Gisbert JP, et al. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012;17 (Suppl 1) 36-42.
13. Ling TK, Leung WK, Lee CC, et al. The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001). Helicobacter 2002;7:327-8. (Pubitemid 35221677)
14. Lee VW, Chau TS, Chan AK, et al. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. J Clin PharmTher 2010;35:343-50.
15. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79.
16. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34.
17. Hsu PI, Wu DC, Wu JY, et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45.
18. Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Ther Adv Gastroenterol 2011;4:103-14.
19. Gatta L, Vakil N, Ricci C, et al. A rapid, low-dose, 13C-urea tablet for the detection of Helicobacter pylori infection before and after treatment. Aliment Pharmacol Ther 2003;17:793-8. (Pubitemid 36418876)
20. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73.
21. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8. (Pubitemid 47196342)
22. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013;25:1134-40.
23. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802-7 e1.
24. Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012;27:504-9.
25. Qian J, Ye F, Zhang J, et al. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012;17:478-85.
26. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13.
27. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
28. McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-9.
29. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82. (Pubitemid 39657940)
30. Yamada S, Onda M, Kat o S, et al. Genetic differences in CYP2C19 single nucloetide polymorphisms among four Asian populations. J Gastroenterol 2001;36:669-72. (Pubitemid 33040939)